PCN79 Cost Effectiveness of Human Papillomavirus Vaccination for the Prevention of Cervical Cancer in Urban Regions of China

Abstract

OBJECTIVES: To determine the costs, outcomes and level of cost-effectiveness associated with HPV vaccination in urban China. METHODS: A Markov model of HPV vaccination in urban China is used to follow hypothetical females from age 12 to age 92. The individuals in the model are assumed to be vaccinated at age 12 and the rates of HPV infection, squamous intraepithelial lesions, cervical cancer and death are measured on an annual basis for 80 years. All costs and outcomes are discounted. RESULTS: In our base case analysis, the administration of HPV vaccine could reduce cervical cancer rate by 65%. In our model, HPV vaccination is found to be cost-saving. The implementation of HPV vaccination results in an increase of 0.6 QALYs over the lifetime of each individual. The total lifetime discounted costs with vaccination are 766 dollars per individual lower than the total costs without vaccination. Under all scenarios examined in our sensitivity analysis, the total costs with vaccination are reduced when compared to current practice with an increase in QALYs as well. CONCLUSIONS: Compared to current practice in China, which does not include cervical cancer screening, HPV vaccination appears to be costsaving. China has a coverage rate of 95% for its childhood immunization program. Incorporating HPV vaccination into this program could likely be done with a minimal amount of effort. Our results provide strong evidence for the implementation of HPV vaccination programs in urban China.